2007
DOI: 10.1007/s10165-007-0627-2
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This multicenter clinical trial was performed to evaluate the efficacy and safety of mizoribine for the treatment of Sjögren's syndrome. Fifty-nine patients with a definite diagnosis of Sjögren's syndrome received 150;Smg of mizoribine daily for 16 weeks. The salivary secretion volume was determined at baseline, at weeks 8 and 16 after the start of the study treatment by the Saxon test, and clinical manifestations were assessed by the investigator and the patients using a 10-cm visual analog scale (VAS). Adver… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
16
0
1

Year Published

2008
2008
2021
2021

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 24 publications
(17 citation statements)
references
References 8 publications
0
16
0
1
Order By: Relevance
“…Mizoribine inhibits the conversion of inosine 5′-nucleotide to guanosine 5′-nucleotide in the purine nucleotide biosynthetic pathway and has similar immunosuppressive effects upon both humoral and cellular immunity to mycophenolate mofetil [9,10,11]. The efficacy of this agent has been demonstrated in patients with diverse conditions including renal transplant recipients [12] and patients with rheumatoid arthritis [13], Sjögren’s syndrome [14], lupus nephritis [15] and primary nephrotic syndrome [16]. Moreover, the incidence of adverse effects including myelosuppression, hepatotoxicity and nephrotoxicity is lower with this drug than other immunosuppressive agents.…”
Section: Introductionmentioning
confidence: 99%
“…Mizoribine inhibits the conversion of inosine 5′-nucleotide to guanosine 5′-nucleotide in the purine nucleotide biosynthetic pathway and has similar immunosuppressive effects upon both humoral and cellular immunity to mycophenolate mofetil [9,10,11]. The efficacy of this agent has been demonstrated in patients with diverse conditions including renal transplant recipients [12] and patients with rheumatoid arthritis [13], Sjögren’s syndrome [14], lupus nephritis [15] and primary nephrotic syndrome [16]. Moreover, the incidence of adverse effects including myelosuppression, hepatotoxicity and nephrotoxicity is lower with this drug than other immunosuppressive agents.…”
Section: Introductionmentioning
confidence: 99%
“…The patients were treated with mizoribine 50 mg t.i.d. for 16 weeks [ 17 ] . The authors noted a signifi cant improvement in salivary secretion volume (measured at 2 min), patients' assessments of dry mouth and dry eye symptoms, and physician global assessment.…”
Section: Mizoribinementioning
confidence: 99%
“…Therefore, it may be useful clinically for the treatment of SS patients in whom excessive activation of B cells has a profound pathogenic effect. Nakayamada et al (14,15) reported that mizoribine significantly improves symptoms such as xerophthalmia as well as accentuating salivary secretions in patients with SS after just 4 months of daily therapy (150 mg/day), and that in addition, the serum IgG level was significantly decreased.…”
Section: B C D Amentioning
confidence: 99%